PubRank

ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Clinical Trial ID NCT02075840

PubWeight™ 27.47‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02075840

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2015 2.60
2 Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015 1.61
3 Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015 1.50
4 Novel ALK inhibitors in clinical use and development. J Hematol Oncol 2015 1.24
5 Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015 1.24
6 Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res 2015 0.99
7 Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun 2015 0.99
8 A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014 0.93
9 Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med 2015 0.88
10 Updates in the management of brain metastases. Neuro Oncol 2016 0.88
11 Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist 2016 0.87
12 ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016 0.86
13 Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience 2016 0.82
14 Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chin J Cancer 2015 0.81
15 Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther Adv Med Oncol 2015 0.80
16 Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Transl Lung Cancer Res 2015 0.80
17 Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016 0.79
18 Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status. BMC Res Notes 2016 0.77
19 Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol 2016 0.77
20 New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. Ther Clin Risk Manag 2016 0.77
21 Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol 2015 0.76
22 Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res 2016 0.76
23 PROFILE 1014: lessons for the new era of lung cancer clinical research. Transl Lung Cancer Res 2015 0.76
24 J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet 2017 0.75
25 Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. Onco Targets Ther 2016 0.75
26 Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. J Thorac Dis 2016 0.75
27 Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016 0.75
28 Alectinib-a new chapter in the management of ALK-positive lung cancer. Transl Lung Cancer Res 2016 0.75
29 Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. Pharmgenomics Pers Med 2015 0.75
30 Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book 2015 0.75
31 Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial". J Thorac Dis 2016 0.75
Next 100